X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23) 23
female (16) 16
male (16) 16
middle aged (16) 16
index medicus (15) 15
aged (13) 13
adult (12) 12
rivaroxaban (10) 10
thrombosis (10) 10
anticoagulants (8) 8
hematology (8) 8
animals (7) 7
thromboembolism (7) 7
drug therapy (6) 6
analysis (5) 5
diagnosis (5) 5
hemorrhage - chemically induced (5) 5
medicine, general & internal (5) 5
patients (5) 5
venous thromboembolism (5) 5
abridged index medicus (4) 4
anticoagulants - adverse effects (4) 4
anticoagulants - therapeutic use (4) 4
embolisms (4) 4
endocrinology & metabolism (4) 4
enoxaparin - adverse effects (4) 4
enoxaparin - therapeutic use (4) 4
factor xa inhibitors - administration & dosage (4) 4
factor xa inhibitors - adverse effects (4) 4
morpholines - adverse effects (4) 4
morpholines - therapeutic use (4) 4
oncology (4) 4
peripheral vascular disease (4) 4
prognosis (4) 4
pulmonary embolism (4) 4
recurrence (4) 4
rivaroxaban - administration & dosage (4) 4
studies (4) 4
thiophenes - adverse effects (4) 4
thiophenes - therapeutic use (4) 4
treatment outcome (4) 4
veins & arteries (4) 4
venous thromboembolism - drug therapy (4) 4
vitamin k - antagonists & inhibitors (4) 4
adolescent (3) 3
anticoagulants - administration & dosage (3) 3
anticoagulation (3) 3
atrial-fibrillation (3) 3
biomedicine (3) 3
biomedicine general (3) 3
biopsy (3) 3
bleeding (3) 3
cancer (3) 3
cancer research (3) 3
carcinoma (3) 3
cardiovascular diseases (3) 3
care and treatment (3) 3
deep-vein thrombosis (3) 3
definition (3) 3
disease (3) 3
double-blind method (3) 3
drug administration schedule (3) 3
drug dosages (3) 3
enoxaparin - administration & dosage (3) 3
factor xa inhibitors - therapeutic use (3) 3
gastroenterology & hepatology (3) 3
health risk assessment (3) 3
hungary (3) 3
immunology (3) 3
morpholines - administration & dosage (3) 3
pancreas (3) 3
pancreatitis - diagnosis (3) 3
pathology (3) 3
physiology (3) 3
research (3) 3
risk factors (3) 3
rivaroxaban - adverse effects (3) 3
rivaroxaban - therapeutic use (3) 3
surgery (3) 3
survival (3) 3
thiophenes - administration & dosage (3) 3
venous thrombosis (3) 3
warfarin (3) 3
acute disease (2) 2
administration, oral (2) 2
age (2) 2
aged, 80 and over (2) 2
arthroplasty (2) 2
aspirin (2) 2
aspirin - administration & dosage (2) 2
bay-59-7939 (2) 2
biochemistry & molecular biology (2) 2
blood pressure (2) 2
cell biology (2) 2
cholecystokinin (2) 2
chronic pancreatitis (2) 2
clinical psychology (2) 2
clinical trials (2) 2
confidence intervals (2) 2
diagnosis, differential (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Journal Article
Thrombosis Journal, ISSN 1477-9560, 11/2014, Volume 12, Issue 1, p. 25
Patients with renal impairment receiving classical anticoagulation for venous thromboembolism (VTE) are at increased risk of bleeding and possibly pulmonary... 
Anticoagulants | Rivaroxaban | Renal insufficiency | Bleeding | Venous thromboembolism | Pharmaceutical industry | Analysis | Studies | Confidence intervals | Embolisms | Blood pressure | Drug therapy | Thrombosis | Drug dosages | Patients
Journal Article
Thrombosis, ISSN 2090-1488, 2011, Volume 2011, pp. 150750 - 6
Prothrombin fragment 1+2 is excreted in urine (uF1+2) as a result of in vivo thrombin generation and can be a marker of coagulation status after an operative... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 2016, Volume 115, Issue 2, pp. 424 - 432
The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin... 
Stroke, Systemic or Venous Thromboembolism | Anticoagulants | Haemorrhage | Thrombosis | Risk factors | Randomised controlled trial | risk factors | ORAL RIVAROXABAN | VALIDATION | randomised controlled trial | ATRIAL-FIBRILLATION | PREDICTION | RIETE REGISTRY | thrombosis | ANTICOAGULANT-THERAPY | WARFARIN | SCORES | PULMONARY-EMBOLISM | anticoagulants | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | ELDERLY-PATIENTS | Prognosis | Anticoagulants - administration & dosage | Humans | Middle Aged | African Americans | Heparin - administration & dosage | Male | Heparin - adverse effects | Enoxaparin - adverse effects | Rivaroxaban - administration & dosage | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Fibrinolytic Agents - adverse effects | Neoplasms - complications | Enoxaparin - administration & dosage | Vitamin K - antagonists & inhibitors | Rivaroxaban - adverse effects | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | Venous Thromboembolism - complications | Female | Platelet Aggregation Inhibitors - adverse effects | Data Interpretation, Statistical | Administration, Oral | Risk Factors | Hemorrhage - complications | Proportional Hazards Models | Treatment Outcome | Anticoagulants - adverse effects | Regression Analysis | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Blood Coagulation - drug effects | Factor Xa Inhibitors - adverse effects | Aged | Fibrinolytic Agents - administration & dosage | Hemorrhage - chemically induced | Hemoglobins - analysis
Journal Article
Thrombosis Research, ISSN 0049-3848, 2016, Volume 149, pp. 29 - 37
Journal Article